MSFT   212.19 (-0.99%)
FB   241.25 (-1.33%)
GOOGL   1,505.56 (-0.86%)
AMZN   3,178.53 (-0.13%)
CGC   16.15 (+0.81%)
BABA   257.02 (-1.74%)
TSLA   1,388.51 (-0.41%)
AMD   57.05 (-0.37%)
T   29.75 (+0.71%)
ACB   11.89 (+1.02%)
GILD   76.15 (+1.93%)
DIS   117.72 (+0.77%)
BA   174.17 (+0.51%)
MSFT   212.19 (-0.99%)
FB   241.25 (-1.33%)
GOOGL   1,505.56 (-0.86%)
AMZN   3,178.53 (-0.13%)
CGC   16.15 (+0.81%)
BABA   257.02 (-1.74%)
TSLA   1,388.51 (-0.41%)
AMD   57.05 (-0.37%)
T   29.75 (+0.71%)
ACB   11.89 (+1.02%)
GILD   76.15 (+1.93%)
DIS   117.72 (+0.77%)
BA   174.17 (+0.51%)
MSFT   212.19 (-0.99%)
FB   241.25 (-1.33%)
GOOGL   1,505.56 (-0.86%)
AMZN   3,178.53 (-0.13%)
CGC   16.15 (+0.81%)
BABA   257.02 (-1.74%)
TSLA   1,388.51 (-0.41%)
AMD   57.05 (-0.37%)
T   29.75 (+0.71%)
ACB   11.89 (+1.02%)
GILD   76.15 (+1.93%)
DIS   117.72 (+0.77%)
BA   174.17 (+0.51%)
MSFT   212.19 (-0.99%)
FB   241.25 (-1.33%)
GOOGL   1,505.56 (-0.86%)
AMZN   3,178.53 (-0.13%)
CGC   16.15 (+0.81%)
BABA   257.02 (-1.74%)
TSLA   1,388.51 (-0.41%)
AMD   57.05 (-0.37%)
T   29.75 (+0.71%)
ACB   11.89 (+1.02%)
GILD   76.15 (+1.93%)
DIS   117.72 (+0.77%)
BA   174.17 (+0.51%)
Log in

NASDAQ:MORFMorphic Stock Price, Forecast & News

$25.96
+0.43 (+1.68 %)
(As of 07/10/2020 09:53 AM ET)
Add
Compare
Today's Range
$25.48
Now: $25.96
$26.14
50-Day Range
$19.50
MA: $23.56
$29.57
52-Week Range
$9.90
Now: $25.96
$33.50
Volume1,131 shs
Average Volume144,867 shs
Market Capitalization$795.67 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Morphic Holding, Inc., a biopharmaceutical company, focuses on the discovery and development of oral small-molecule integrin therapeutics. The company's lead product candidates in clinical development are MORF-720, a selective oral avb6 specific integrin inhibitor for the treatment of idiopathic pulmonary fibrosis; and a4b7 specific integrin inhibitors for the treatment of inflammatory bowel disease. Its product candidates in discovery stage include an avb1 integrin for the treatment of fibrosis; two TGF-b activations for gastrointestinal cancers and fibrosis; and other aI domain integrins. The company was founded in 2014 and is headquartered in Waltham, Massachusetts.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 2.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.36 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MORF
CUSIPN/A
CIKN/A
Phone781-996-0955

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$16.98 million
Book Value$4.62 per share

Profitability

Net Income$-43,330,000.00

Miscellaneous

Employees59
Market Cap$795.67 million
Next Earnings Date8/10/2020 (Estimated)
OptionableNot Optionable

Receive MORF News and Ratings via Email

Sign-up to receive the latest news and ratings for MORF and its competitors with MarketBeat's FREE daily newsletter.

Morphic (NASDAQ:MORF) Frequently Asked Questions

How has Morphic's stock been impacted by COVID-19 (Coronavirus)?

Morphic's stock was trading at $14.41 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, MORF stock has increased by 80.2% and is now trading at $25.96. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Morphic?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Morphic in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Morphic.

When is Morphic's next earnings date?

Morphic is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for Morphic.

How were Morphic's earnings last quarter?

Morphic Holding (NASDAQ:MORF) issued its earnings results on Wednesday, May, 6th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.48) by $0.07. The business earned $5.59 million during the quarter, compared to analysts' expectations of $3.80 million. View Morphic's earnings history.

What price target have analysts set for MORF?

4 brokerages have issued 12 month price targets for Morphic's stock. Their forecasts range from $32.00 to $32.00. On average, they expect Morphic's stock price to reach $32.00 in the next twelve months. This suggests a possible upside of 23.3% from the stock's current price. View analysts' price targets for Morphic.

Has Morphic been receiving favorable news coverage?

News articles about MORF stock have trended somewhat positive this week, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Morphic earned a news impact score of 1.8 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news about Morphic.

Are investors shorting Morphic?

Morphic saw a increase in short interest in June. As of June 30th, there was short interest totaling 559,600 shares, an increase of 24.8% from the June 15th total of 448,400 shares. Based on an average daily volume of 71,000 shares, the short-interest ratio is currently 7.9 days. Approximately 4.5% of the shares of the company are sold short. View Morphic's Current Options Chain.

Who are some of Morphic's key competitors?

What other stocks do shareholders of Morphic own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Morphic investors own include AbbVie (ABBV), Gilead Sciences (GILD), NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), AT&T (T), Axsome Therapeutics (AXSM), Atreca (BCEL), Carnival (CCL), Canopy Growth (CGC) and Clovis Oncology (CLVS).

Who are Morphic's key executives?

Morphic's management team includes the following people:
  • Dr. Praveen P. Tipirneni M.D., CEO, Pres & Director (Age 50)
  • Dr. Timothy A. Springer Ph.D., Founder, Director & Member of Scientific Advisory Board (Age 71)
  • Mr. Robert E. Farrell Jr., CPA, CPA, VP of Fin. & Operations and Treasurer (Age 54)
  • Dr. Bruce N. Rogers, Chief Scientific Officer (Age 50)
  • Mr. William D. DeVaul Esq., Gen. Counsel & Sec. (Age 48)

When did Morphic IPO?

(MORF) raised $75 million in an initial public offering on Thursday, June 27th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Jefferies, Cowen, BMO Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO.

What is Morphic's stock symbol?

Morphic trades on the NASDAQ under the ticker symbol "MORF."

How do I buy shares of Morphic?

Shares of MORF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Morphic's stock price today?

One share of MORF stock can currently be purchased for approximately $25.96.

How big of a company is Morphic?

Morphic has a market capitalization of $795.67 million and generates $16.98 million in revenue each year. The company earns $-43,330,000.00 in net income (profit) each year or ($2.69) on an earnings per share basis. Morphic employs 59 workers across the globe.

What is Morphic's official website?

The official website for Morphic is www.morphictx.com.

How can I contact Morphic?

Morphic's mailing address is 35 Gatehouse Drive A2, Waltham MA, 02451. The company can be reached via phone at 781-996-0955.

This page was last updated on 7/10/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.